Free tool
FAERS Monitor: Xenleta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211673 or its brand name (Xenleta, Lefamulin Acetate). Reports on generic versions are filed under their own applications.
Reports
55
Serious
35
64% of reports
Hospitalization
5
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use27
- drug hypersensitivity26
- product use in unapproved indication26
- toxic epidermal necrolysis25
- diarrhoea7
- vomiting7
- hypotension6
- pain5
- dyspnoea4
- hypersensitivity4
- condition aggravated3
- death3
- drug ineffective3
- headache3
- nausea3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 3 |
| 2011 | 1 |
| 2020 | 18 |
| 2021 | 17 |
| 2022 | 8 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,104 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| toxic epidermal necrolysisSignal | 25 | 630.6 | 471.9 | 15,077 |
| drug hypersensitivitySignal | 26 | 51.4 | 38.9 | 1,246 |
| product use in unapproved indicationSignal | 26 | 40.1 | 30.3 | 964 |
| off label useSignal | 27 | 11.8 | 9.0 | 267 |
| hypotensionSignal | 6 | 11.4 | 5.4 | 48 |
| hypersensitivitySignal | 4 | 8.2 | 3.2 | 19 |
| vomitingSignal | 7 | 5.7 | 2.8 | 23 |
| diarrhoeaSignal | 7 | 4.1 | 2.1 | 14 |
| condition aggravated | 3 | 3.8 | 1.3 | 4 |
| painSignal | 5 | 3.1 | 1.3 | 5 |
| dyspnoea | 4 | 2.7 | 1.1 | 3 |
| headache | 3 | 1.8 | 0.6 | 0 |
| nausea | 3 | 1.4 | 0.5 | 0 |
| death | 3 | 1.3 | 0.4 | 0 |
| drug ineffective | 3 | 0.9 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.